{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,23]],"date-time":"2026-07-23T09:00:42Z","timestamp":1784797242552,"version":"3.55.0"},"reference-count":80,"publisher":"Oxford University Press (OUP)","issue":"5","license":[{"start":{"date-parts":[[2024,12,19]],"date-time":"2024-12-19T00:00:00Z","timestamp":1734566400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"funder":[{"name":"Takeda Pharma A\/S"},{"name":"Louis-Hansen Foundation"},{"DOI":"10.13039\/501100009708","name":"Novo Nordisk Foundation","doi-asserted-by":"publisher","award":["NNF22OC0074080"],"award-info":[{"award-number":["NNF22OC0074080"]}],"id":[{"id":"10.13039\/501100009708","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,5,8]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background and Aims<\/jats:title>\n                    <jats:p>Existing findings on outcomes of anti-tumor-necrosis-factor (TNF) therapy in patients with inflammatory bowel diseases (IBD) are largely based on retrospective studies. We aimed to investigate real-world outcomes of anti-TNF therapy and predictors thereof in a prospective IBD cohort.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>In a Danish multicenter cohort of adult bio-na\u00efve patients with IBD treated with anti-TNF, we assessed clinical response and remission to induction therapy using clinical disease activity scoring indices at Week 14. In patients who continued treatment beyond the induction period, we also assessed loss of response (LOR), drug withdrawal, and major IBD surgery during maintenance therapy.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>This study included 774 patients (706 infliximab, 68 adalimumab) followed for a median duration of 125 weeks Clinical response was achieved in 209\/331 (67.4%) of ulcerative colitis (UC) and 125\/197 (74.0%) of Crohn\u2019s disease (CD) patients, while 143\/331 (46.1%) UC and 81\/197 (47.9%) CD patients achieved clinical remission. In 294 UC and 309 CD patients received maintenance therapy, while 86\/294 (29.3%) UC and 78\/309 (25.2%) CD patients experienced LOR. Active smoking and less severe disease activity predicted favorable outcomes in UC, while short disease duration, colonic disease, nonstricturing behavior, and concomitant immunomodulator therapy predicted favorable outcomes in CD.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Clinical response was achieved in 2 in 3 UC and 3 in 4 CD patients, meanwhile, one-third of UC and one-fourth of CD patients experienced LOR despite the short disease duration in this study. Several clinical features were associated with outcomes and may be useful predictors of anti-TNF treatment response.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/ecco-jcc\/jjae192","type":"journal-article","created":{"date-parts":[[2024,12,18]],"date-time":"2024-12-18T07:34:49Z","timestamp":1734507289000},"source":"Crossref","is-referenced-by-count":12,"title":["Clinical Outcomes After First-Line Anti- Tumor-Necrosis-Factor Treatment of Patients With Inflammatory Bowel Disease\u2014A Prospective Multicenter Cohort Study"],"prefix":"10.1093","volume":"19","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8392-4860","authenticated-orcid":false,"given":"Mirabella","family":"Zhao","sequence":"first","affiliation":[{"name":"Gastrounit, Medical Section,\u00a0Copenhagen University Hospital\u2014Amager and Hvidovre , Hvidovre ,","place":["Denmark"]},{"name":"Copenhagen Center for Inflammatory Bowel Disease in Children, Adolescents and Adults, Gastrounit, Medical Section, Copenhagen University Hospital\u2014Amager and Hvidovre , Hvidovre ,","place":["Denmark"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4067-2381","authenticated-orcid":false,"given":"Lone","family":"Larsen","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology and Hepatology, Aalborg University Hospital , Aalborg ,","place":["Denmark"]},{"name":"Department of Clinical Medicine, Center for Molecular Prediction of Inflammatory Bowel Disease, PREDICT, Aalborg University , Copenhagen ,","place":["Denmark"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anders","family":"Dige","sequence":"additional","affiliation":[{"name":"Department of Hepatology and Gastroenterology, Aarhus University Hospital , Aarhus ,","place":["Denmark"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0314-3467","authenticated-orcid":false,"given":"Anja","family":"Poulsen","sequence":"additional","affiliation":[{"name":"Digestive Disease Center,\u00a0Copenhagen University Hospital, Bispebjerg and Frederiksberg Hospital , Copenhagen ,","place":["Denmark"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bobby","family":"Lo","sequence":"additional","affiliation":[{"name":"Gastrounit, Medical Section,\u00a0Copenhagen University Hospital\u2014Amager and Hvidovre , Hvidovre ,","place":["Denmark"]},{"name":"Copenhagen Center for Inflammatory Bowel Disease in Children, Adolescents and Adults, Gastrounit, Medical Section, Copenhagen University Hospital\u2014Amager and Hvidovre , Hvidovre ,","place":["Denmark"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0323-7030","authenticated-orcid":false,"given":"Mohamed","family":"Attauabi","sequence":"additional","affiliation":[{"name":"Copenhagen Center for Inflammatory Bowel Disease in Children, Adolescents and Adults, Gastrounit, Medical Section, Copenhagen University Hospital\u2014Amager and Hvidovre , Hvidovre ,","place":["Denmark"]},{"name":"Department of Gastroenterology and Hepatology, Copenhagen University Hospital, Herlev and Gentofte Hospital , Herlev ,","place":["Denmark"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pernille Dige","family":"Ovesen","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology and Hepatology, Copenhagen University Hospital, Herlev and Gentofte Hospital , Herlev ,","place":["Denmark"]},{"name":"Department of Clinical Medicine, Faculty of Health and Medical Sciences, University of Copenhagen , Copenhagen ,","place":["Denmark"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mads Damsgaard","family":"Wewer","sequence":"additional","affiliation":[{"name":"Copenhagen Center for Inflammatory Bowel Disease in Children, Adolescents and Adults, Gastrounit, Medical Section, Copenhagen University Hospital\u2014Amager and Hvidovre , Hvidovre ,","place":["Denmark"]},{"name":"Department of Gastroenterology and Hepatology, Copenhagen University Hospital, Herlev and Gentofte Hospital , Herlev ,","place":["Denmark"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dagmar","family":"Christiansen","sequence":"additional","affiliation":[{"name":"Digestive Disease Center,\u00a0Copenhagen University Hospital, Bispebjerg and Frederiksberg Hospital , Copenhagen ,","place":["Denmark"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian Lodberg","family":"Hvas","sequence":"additional","affiliation":[{"name":"Department of Hepatology and Gastroenterology, Aarhus University Hospital , Aarhus ,","place":["Denmark"]},{"name":"Department of Clinical Medicine, Health, Aarhus University , Aarhus ,","place":["Denmark"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andreas Munk","family":"Petersen","sequence":"additional","affiliation":[{"name":"Gastrounit, Medical Section,\u00a0Copenhagen University Hospital\u2014Amager and Hvidovre , Hvidovre ,","place":["Denmark"]},{"name":"Copenhagen Center for Inflammatory Bowel Disease in Children, Adolescents and Adults, Gastrounit, Medical Section, Copenhagen University Hospital\u2014Amager and Hvidovre , Hvidovre ,","place":["Denmark"]},{"name":"Department of Clinical Medicine, Faculty of Health and Medical Sciences, University of Copenhagen , Copenhagen ,","place":["Denmark"]},{"name":"Department of Clinical Microbiology, Copenhagen University Hospital\u2013Amager and Hvidovre , Hvidovre ,","place":["Denmark"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Flemming","family":"Bendtsen","sequence":"additional","affiliation":[{"name":"Gastrounit, Medical Section,\u00a0Copenhagen University Hospital\u2014Amager and Hvidovre , Hvidovre ,","place":["Denmark"]},{"name":"Copenhagen Center for Inflammatory Bowel Disease in Children, Adolescents and Adults, Gastrounit, Medical Section, Copenhagen University Hospital\u2014Amager and Hvidovre , Hvidovre ,","place":["Denmark"]},{"name":"Department of Clinical Medicine, Faculty of Health and Medical Sciences, University of Copenhagen , Copenhagen ,","place":["Denmark"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3230-7966","authenticated-orcid":false,"given":"Jakob","family":"Seidelin","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology and Hepatology, Copenhagen University Hospital, Herlev and Gentofte Hospital , Herlev ,","place":["Denmark"]},{"name":"Department of Clinical Medicine, Faculty of Health and Medical Sciences, University of Copenhagen , Copenhagen ,","place":["Denmark"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3312-5139","authenticated-orcid":false,"given":"Johan","family":"Burisch","sequence":"additional","affiliation":[{"name":"Gastrounit, Medical Section,\u00a0Copenhagen University Hospital\u2014Amager and Hvidovre , Hvidovre ,","place":["Denmark"]},{"name":"Copenhagen Center for Inflammatory Bowel Disease in Children, Adolescents and Adults, Gastrounit, Medical Section, Copenhagen University Hospital\u2014Amager and Hvidovre , Hvidovre ,","place":["Denmark"]},{"name":"Department of Clinical Medicine, Faculty of Health and Medical Sciences, University of Copenhagen , Copenhagen ,","place":["Denmark"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2024,12,19]]},"reference":[{"key":"2026072304012636500_CIT0001","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1093\/ecco-jcc\/jjv190","article-title":"Impact of new treatments on hospitalisation, surgery, infection, and mortality in IBD: a Focus paper by the epidemiology committee of ECCO","volume":"10","author":"Annese","year":"2016","journal-title":"J Crohns Colitis"},{"key":"2026072304012636500_CIT0002","doi-asserted-by":"crossref","first-page":"1396","DOI":"10.1136\/gutjnl-2019-320022","article-title":"25 years of anti-TNF treatment for inflammatory bowel disease: lessons from the past and a look to the future","volume":"70","author":"D\u2019Haens","year":"2021","journal-title":"Gut"},{"key":"2026072304012636500_CIT0003","doi-asserted-by":"crossref","first-page":"977","DOI":"10.1111\/apt.13363","article-title":"Impact of the early use of immunomodulators or TNF antagonists on bowel damage and surgery in Crohn\u2019s disease","volume":"42","author":"Safroneeva","year":"2015","journal-title":"Aliment Pharmacol Ther"},{"key":"2026072304012636500_CIT0004","doi-asserted-by":"crossref","first-page":"1788","DOI":"10.1016\/j.cgh.2018.11.003","article-title":"Upfront combination therapy, compared with monotherapy, for patients not previously treated with a biologic agent associates with reduced risk of inflammatory bowel disease-related complications in a population-based cohort study","volume":"17","author":"Targownik","year":"2019","journal-title":"Clin Gastroenterol Hepatol"},{"key":"2026072304012636500_CIT0005","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1177\/17562848211006669","article-title":"Novel trends with biologics in inflammatory bowel disease: sequential and combined approaches","volume":"14","author":"Privitera","year":"2021","journal-title":"Therap Adv Gastroenterol"},{"key":"2026072304012636500_CIT0006","doi-asserted-by":"crossref","first-page":"1002","DOI":"10.1016\/S2468-1253(21)00312-5","article-title":"Comparative efficacy and safety of biologic therapies for moderate-to-severe Crohn\u2019s disease: a systematic review and network meta-analysis","volume":"6","author":"Singh","year":"2021","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"2026072304012636500_CIT0007","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/S2468-1253(21)00377-0","article-title":"Efficacy and safety of biologics and small molecule drugs for patients with moderate-to-severe ulcerative colitis: a systematic review and network meta-analysis","volume":"7","author":"Lasa","year":"2022","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"2026072304012636500_CIT0008","doi-asserted-by":"crossref","first-page":"5318","DOI":"10.3390\/jcm10225318","article-title":"Primary failure to an anti-TNF agent in inflammatory bowel disease: switch (to a second anti-TNF agent) or swap (for another mechanism of action)","volume":"10","author":"Gisbert","year":"2021","journal-title":"J Clin Med"},{"key":"2026072304012636500_CIT0009","first-page":"656","article-title":"Etiology and management of lack or loss of response to anti\u2013tumor necrosis factor therapy in patients with inflammatory bowel disease","volume":"15","author":"Fine","year":"2019","journal-title":"Gastroenterol Hepatol"},{"key":"2026072304012636500_CIT0010","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1111\/apt.16723","article-title":"Trends in the use of biologicals and their treatment outcomes among patients with inflammatory bowel diseases\u2014a Danish nationwide cohort study","volume":"55","author":"Zhao","year":"2022","journal-title":"Aliment Pharmacol Ther"},{"key":"2026072304012636500_CIT0011","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1093\/ecco-jcc\/jjy004","article-title":"Primary non-response to tumor necrosis factor antagonists is associated with inferior response to second-line biologics in patients with inflammatory bowel diseases: a systematic review and meta-analysis","volume":"12","author":"Singh","year":"2018","journal-title":"J Crohns Colitis"},{"key":"2026072304012636500_CIT0012","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1038\/s41575-021-00543-0","article-title":"Revisiting fibrosis in inflammatory bowel disease: the gut thickens","volume":"19","author":"D\u2019Alessio","year":"2022","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"2026072304012636500_CIT0013","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1111\/apt.16478","article-title":"Limited long-term treatment persistence of first anti-TNF therapy in 538 patients with inflammatory bowel diseases: a 20-year real-world study","volume":"54","author":"Blesl","year":"2021","journal-title":"Aliment Pharmacol Ther"},{"key":"2026072304012636500_CIT0014","doi-asserted-by":"crossref","first-page":"826","DOI":"10.1016\/j.cgh.2013.01.012","article-title":"Adalimumab and infliximab are equally effective for Crohn\u2019s disease in patients not previously treated with anti-tumor necrosis factor-\u03b1 agents","volume":"11","author":"Kestens","year":"2013","journal-title":"Clin Gastroenterol Hepatol"},{"key":"2026072304012636500_CIT0015","doi-asserted-by":"crossref","first-page":"1454","DOI":"10.1016\/j.crohns.2014.05.007","article-title":"Crohn\u2019s disease outpatients treated with adalimumab have an earlier secondary loss of response and requirement for dose escalation compared to infliximab: a real life cohort study","volume":"8","author":"Ma","year":"2014","journal-title":"J Crohns Colitis"},{"key":"2026072304012636500_CIT0016","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1016\/j.crohns.2011.07.011","article-title":"Efficacy, tolerability, and predictors of response to infliximab therapy for Crohn\u2019s disease: a large single centre experience","volume":"6","author":"Sprakes","year":"2012","journal-title":"J Crohns Colitis"},{"key":"2026072304012636500_CIT0017","doi-asserted-by":"crossref","first-page":"1452","DOI":"10.1093\/ibd\/izaa309","article-title":"Early changes in serum albumin predict clinical and endoscopic outcomes in patients with ulcerative colitis starting anti-TNF treatment","volume":"27","author":"Lee","year":"2021","journal-title":"Inflamm Bowel Dis"},{"key":"2026072304012636500_CIT0018","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1016\/j.dld.2021.06.005","article-title":"Treatment patterns and intensification within 5 year of follow-up of the first-line anti-TNF\u03b1 used for the treatment of IBD: results from the VERNE study","volume":"54","author":"Bastida","year":"2022","journal-title":"Dig Liver Dis"},{"key":"2026072304012636500_CIT0019","doi-asserted-by":"crossref","first-page":"3282","DOI":"10.3748\/wjg.v21.i11.3282","article-title":"Real-life outcome of anti-tumor necrosis factor \u03b1 in the ambulatory treatment of ulcerative colitis","volume":"21","author":"Baki","year":"2015","journal-title":"World J Gastroenterol"},{"key":"2026072304012636500_CIT0020","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1016\/j.cgh.2014.07.055","article-title":"A panel to predict long-term outcome of infliximab therapy for patients with ulcerative colitis","volume":"13","author":"Arias","year":"2015","journal-title":"Clin Gastroenterol Hepatol"},{"key":"2026072304012636500_CIT0021","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1111\/apt.13893","article-title":"Long-term outcome of infliximab treatment in chronic active ulcerative colitis: a Swedish multicentre study of 250 patients","volume":"45","author":"Angelison","year":"2017","journal-title":"Aliment Pharmacol Ther"},{"key":"2026072304012636500_CIT0022","doi-asserted-by":"crossref","first-page":"1368","DOI":"10.1097\/MIB.0000000000000115","article-title":"Long-term combination therapy with infliximab plus azathioprine predicts sustained steroid-free clinical benefit in steroid-dependent ulcerative colitis","volume":"20","author":"Armuzzi","year":"2014","journal-title":"Inflamm Bowel Dis"},{"key":"2026072304012636500_CIT0023","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1093\/ecco-jcc\/jjw008","article-title":"Anti-TNF monotherapy for Crohn\u2019s disease: a 13-year multicentre experience","volume":"10","author":"Peyrin-Biroulet","year":"2016","journal-title":"J Crohns Colitis"},{"key":"2026072304012636500_CIT0024","doi-asserted-by":"crossref","first-page":"880","DOI":"10.1097\/MIB.0000000000000754","article-title":"Comparative effectiveness of infliximab and adalimumab in Crohn\u2019s disease and ulcerative colitis","volume":"22","author":"Ananthakrishnan","year":"2016","journal-title":"Inflamm Bowel Dis"},{"key":"2026072304012636500_CIT0025","doi-asserted-by":"crossref","first-page":"1002","DOI":"10.1016\/j.cgh.2012.02.004","article-title":"Patients enrolled in randomized controlled trials do not represent the inflammatory bowel disease patient population","volume":"10","author":"Ha","year":"2012","journal-title":"Clin Gastroenterol Hepatol"},{"key":"2026072304012636500_CIT0026","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1016\/S2468-1253(19)30012-3","article-title":"Predictors of anti-TNF treatment failure in anti-TNF-naive patients with active luminal Crohn\u2019s disease: a prospective, multicentre, cohort study","volume":"4","author":"Kennedy","year":"2019","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"2026072304012636500_CIT0027","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1093\/ecco-jcc\/jjv220","article-title":"Efficacy and safety of the biosimilar infliximab CT-P13 treatment in inflammatory bowel diseases: a prospective, multicentre, nationwide cohort","volume":"10","author":"Gecse","year":"2016","journal-title":"J Crohns Colitis"},{"key":"2026072304012636500_CIT0028","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1093\/ecco-jcc\/jjv169","article-title":"Efficacy and safety of adalimumab in ulcerative colitis refractory to conventional therapy in routine clinical practice","volume":"10","author":"B\u00e1lint","year":"2016","journal-title":"J Crohns Colitis"},{"key":"2026072304012636500_CIT0029","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1111\/apt.14125","article-title":"The benefit of combination therapy depends on disease phenotype and duration in Crohn\u2019s disease","volume":"46","author":"Ananthakrishnan","year":"2017","journal-title":"Aliment Pharmacol Ther"},{"key":"2026072304012636500_CIT0030","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1111\/apt.13671","article-title":"The efficacy and safety of either infliximab or adalimumab in 362 patients with anti-TNF-\u03b1 na\u00efve Crohn\u2019s disease","volume":"44","author":"Narula","year":"2016","journal-title":"Aliment Pharmacol Ther"},{"key":"2026072304012636500_CIT0031","doi-asserted-by":"crossref","first-page":"884","DOI":"10.1080\/00365521.2020.1786852","article-title":"Therapeutic thresholds and mechanisms for primary non-response to infliximab in inflammatory bowel disease","volume":"55","author":"Buhl","year":"2020","journal-title":"Scand J Gastroenterol"},{"key":"2026072304012636500_CIT0032","doi-asserted-by":"crossref","first-page":"e035756","DOI":"10.1136\/bmjopen-2019-035756","article-title":"Predictors of response and disease course in patients with inflammatory bowel disease treated with biological therapy\u2014the Danish IBD Biobank Project: protocol for a multicentre prospective cohort study","volume":"10","author":"Zhao","year":"2020","journal-title":"BMJ Open"},{"key":"2026072304012636500_CIT0033","author":"The Danish Medicine\u2019s Council (Medicinerr\u00e5det)","year":"2019","journal-title":"Treatment recommendation for the management of inflammatory bowel diseases (IBD) with expensive hospital medicines [Internet]"},{"key":"2026072304012636500_CIT0034","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1016\/j.jbi.2008.08.010","article-title":"Research electronic data capture (REDCap): a metadata-driven methodology and workflow process for providing translational research informatics support","volume":"42","author":"Harris","year":"2009","journal-title":"J Biomed Inform"},{"key":"2026072304012636500_CIT0035","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1155\/2005\/269076","article-title":"Toward an integrated clinical, molecular and serological classification of inflammatory bowel disease: report of a Working Party of the 2005 Montreal World Congress of Gastroenterology","volume":"19","author":"Silverberg","year":"2005","journal-title":"Can J Gastroenterol"},{"key":"2026072304012636500_CIT0036","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1136\/gut.43.1.29","article-title":"A simple clinical colitis activity index","volume":"43","author":"Walmsley","year":"1998","journal-title":"Gut"},{"key":"2026072304012636500_CIT0037","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1016\/S0140-6736(80)92767-1","article-title":"A simple index of Crohn\u2019s-disease activity","volume":"315","author":"Harvey","year":"1980","journal-title":"Lancet"},{"key":"2026072304012636500_CIT0038","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1136\/bmj.2.4884.375","article-title":"Cortisone in ulcerative colitis preliminary report on a therapeutic trial","volume":"2","author":"Truelove","year":"1954","journal-title":"Br Med J"},{"key":"2026072304012636500_CIT0039","doi-asserted-by":"crossref","first-page":"1541","DOI":"10.1016\/S0140-6736(02)08512-4","article-title":"Maintenance infliximab for Crohn\u2019s disease: the ACCENT I randomised trial","volume":"359","author":"Hanauer","year":"2002","journal-title":"Lancet"},{"key":"2026072304012636500_CIT0040","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1053\/j.gastro.2006.11.041","article-title":"Adalimumab for maintenance of clinical response and remission in patients with Crohn\u2019s disease: the CHARM trial","volume":"132","author":"Colombel","year":"2007","journal-title":"Gastroenterology"},{"key":"2026072304012636500_CIT0041","doi-asserted-by":"crossref","first-page":"998","DOI":"10.1136\/gut.52.7.998","article-title":"Infliximab in moderately severe glucocorticoid resistant ulcerative colitis: a randomised controlled trial","volume":"52","author":"Probert","year":"2003","journal-title":"Gut"},{"key":"2026072304012636500_CIT0042","doi-asserted-by":"crossref","first-page":"2462","DOI":"10.1056\/NEJMoa050516","article-title":"Infliximab for induction and maintenance therapy for ulcerative colitis","volume":"353","author":"Rutgeerts","year":"2005","journal-title":"N Engl J Med"},{"key":"2026072304012636500_CIT0043","doi-asserted-by":"crossref","first-page":"1065","DOI":"10.1097\/MIB.0b013e3182802909","article-title":"Infliximab in steroid-dependent ulcerative colitis: effectiveness and predictors of clinical and endoscopic remission","volume":"19","author":"Armuzzi","year":"2013","journal-title":"Inflamm Bowel Dis"},{"key":"2026072304012636500_CIT0044","doi-asserted-by":"crossref","first-page":"1694","DOI":"10.1093\/ecco-jcc\/jjab058","article-title":"Vedolizumab and anti-tumour necrosis factor \u03b1 real-world outcomes in biologic-na\u00efve inflammatory bowel disease patients: results from the EVOLVE study","volume":"15","author":"Bressler","year":"2021","journal-title":"J Crohns Colitis"},{"key":"2026072304012636500_CIT0045","doi-asserted-by":"crossref","first-page":"2779","DOI":"10.1016\/S0140-6736(17)32641-7","article-title":"Effect of tight control management on Crohn\u2019s disease (CALM): a multicentre, randomised, controlled phase 3 trial","volume":"390","author":"Colombel","year":"2017","journal-title":"Lancet"},{"key":"2026072304012636500_CIT0046","doi-asserted-by":"crossref","first-page":"870","DOI":"10.1097\/MIB.0000000000000679","article-title":"Anti-TNF therapy within 2 years of Crohn\u2019s disease diagnosis improves patient outcomes: a retrospective cohort study","volume":"22","author":"Ma","year":"2016","journal-title":"Inflamm Bowel Dis"},{"key":"2026072304012636500_CIT0047","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1111\/j.1365-2036.2011.04612.x","article-title":"Review article: loss of response to anti-TNF treatments in Crohn\u2019s disease","volume":"33","author":"Ben-Horin","year":"2011","journal-title":"Aliment Pharmacol Ther"},{"key":"2026072304012636500_CIT0048","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1007\/s00535-017-1324-3","article-title":"Systematic review with meta-analysis: loss of response and requirement of anti-TNF\u03b1 dose intensification in Crohn\u2019s disease","volume":"52","author":"Qiu","year":"2017","journal-title":"J Gastroenterol"},{"key":"2026072304012636500_CIT0049","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1016\/j.crohns.2010.09.004","article-title":"Treatment of acute ulcerative colitis with infliximab, a retrospective study from three Danish hospitals","volume":"5","author":"Mortensen","year":"2011","journal-title":"J Crohns Colitis"},{"key":"2026072304012636500_CIT0050","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1111\/apt.13445","article-title":"Systematic review: predicting and optimising response to anti-TNF therapy in Crohn\u2019s disease\u2014algorithm for practical management","volume":"43","author":"Ding","year":"2016","journal-title":"Aliment Pharmacol Ther"},{"key":"2026072304012636500_CIT0051","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1016\/j.crohns.2012.05.015","article-title":"Subgroup analysis of the placebo-controlled CHARM trial: increased remission rates through 3 years for adalimumab-treated patients with early Crohn\u2019s disease","volume":"7","author":"Schreiber","year":"2013","journal-title":"J Crohns Colitis"},{"key":"2026072304012636500_CIT0052","doi-asserted-by":"crossref","first-page":"2225","DOI":"10.1002\/ibd.22925","article-title":"Response to biologic therapy in Crohn\u2019s disease is improved with early treatment: an analysis of health claims data","volume":"18","author":"Rubin","year":"2012","journal-title":"Inflamm Bowel Dis"},{"key":"2026072304012636500_CIT0053","doi-asserted-by":"crossref","first-page":"734","DOI":"10.1111\/apt.13139","article-title":"Randomised clinical trial: deep remission in biologic and immunomodulator na\u00efve patients with Crohn\u2019s disease: A SONIC post hoc analysis","volume":"41","author":"Colombel","year":"2015","journal-title":"Aliment Pharmacol Ther"},{"key":"2026072304012636500_CIT0054","doi-asserted-by":"crossref","first-page":"660","DOI":"10.1016\/S0140-6736(08)60304-9","article-title":"Early combined immunosuppression or conventional management in patients with newly diagnosed Crohn\u2019s disease: an open randomised trial","volume":"371","author":"D\u2019Haens","year":"2008","journal-title":"Lancet"},{"key":"2026072304012636500_CIT0055","doi-asserted-by":"crossref","first-page":"1825","DOI":"10.1016\/S0140-6736(15)00068-9","article-title":"Early combined immunosuppression for the management of Crohn\u2019s disease (REACT): a cluster randomised controlled trial","volume":"386","author":"Khanna","year":"2015","journal-title":"Lancet"},{"key":"2026072304012636500_CIT0056","doi-asserted-by":"crossref","first-page":"482","DOI":"10.1053\/j.gastro.2021.10.037","article-title":"Efficacy of biologic drugs in short-duration versus long-duration inflammatory bowel disease: a systematic review and an individual-patient data meta-analysis of randomized controlled trials","volume":"162","author":"Ben-Horin","year":"2022","journal-title":"Gastroenterology"},{"key":"2026072304012636500_CIT0057","first-page":"1","article-title":"A biomarker-stratified comparison of top-down versus accelerated step-up treatment strategies for patients with newly diagnosed Crohn\u2019s disease (PROFILE): a multi-centre, open-label randomised controlled trial","volume":"1253","author":"Noor","year":"2024","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"2026072304012636500_CIT0058","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1111\/apt.15685","article-title":"Systematic review and meta-analysis: efficacy and safety of early biologic treatment in adult and paediatric patients with Crohn\u2019s disease","volume":"51","author":"Ungaro","year":"2020","journal-title":"Aliment Pharmacol Ther"},{"key":"2026072304012636500_CIT0059","doi-asserted-by":"crossref","first-page":"e024222","DOI":"10.1136\/bmjopen-2018-024222","article-title":"Efficacy of biological drugs in short-duration versus long-duration inflammatory bowel disease: a protocol for a systematic review and an individual-patient level meta-analysis of randomised controlled trials","volume":"9","author":"Ben-Horin","year":"2019","journal-title":"BMJ Open"},{"key":"2026072304012636500_CIT0060","doi-asserted-by":"crossref","first-page":"382","DOI":"10.3349\/ymj.2020.61.5.382","article-title":"Similar clinical outcomes of early and late anti-TNF initiation for ulcerative colitis: a nationwide population-based study","volume":"61","author":"Han","year":"2020","journal-title":"Yonsei Med J"},{"key":"2026072304012636500_CIT0061","doi-asserted-by":"crossref","first-page":"1383","DOI":"10.1056\/NEJMoa0904492","article-title":"Infliximab, azathioprine, or combination therapy for Crohn\u2019s disease","volume":"362","author":"Fr\u00e9d\u00e9ric Colombel","year":"2010","journal-title":"N Engl J Med"},{"key":"2026072304012636500_CIT0062","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1053\/j.gastro.2013.10.052","article-title":"Combination therapy with infliximab and azathioprine is superior to monotherapy with either agent in ulcerative colitis","volume":"146","author":"Panaccione","year":"2014","journal-title":"Gastroenterology"},{"key":"2026072304012636500_CIT0063","doi-asserted-by":"crossref","first-page":"1354","DOI":"10.1093\/ecco-jcc\/jjaa050","article-title":"Combined biologic and immunomodulatory therapy is superior to monotherapy for decreasing the risk of inflammatory bowel disease-related complications","volume":"14","author":"Targownik","year":"2020","journal-title":"J Crohns Colitis"},{"key":"2026072304012636500_CIT0064","doi-asserted-by":"crossref","first-page":"1451","DOI":"10.1046\/j.1365-2036.2003.01574.x","article-title":"An analysis of factors influencing short-term and sustained response to infliximab treatment for Crohn\u2019s disease","volume":"17","author":"Arnott","year":"2003","journal-title":"Aliment Pharmacol Ther"},{"key":"2026072304012636500_CIT0065","doi-asserted-by":"crossref","first-page":"1382","DOI":"10.1097\/MIB.0000000000001150","article-title":"Colonic phenotypes are associated with poorer response to anti-TNF therapies in patients with IBD","volume":"23","author":"Yoon","year":"2017","journal-title":"Inflamm Bowel Dis"},{"key":"2026072304012636500_CIT0066","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1016\/S0140-6736(15)00465-1","article-title":"Inherited determinants of Crohn\u2019s disease and ulcerative colitis phenotypes: a genetic association study","volume":"387","author":"Cleynen","year":"2016","journal-title":"Lancet"},{"key":"2026072304012636500_CIT0067","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1038\/s41575-021-00424-6","article-title":"Location is important: differentiation between ileal and colonic Crohn\u2019s disease","volume":"18","author":"Atreya","year":"2021","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"2026072304012636500_CIT0068","doi-asserted-by":"crossref","first-page":"2247","DOI":"10.1097\/MIB.0000000000000212","article-title":"Patient factors that increase infliximab clearance and shorten half-life in inflammatory bowel disease: a population pharmacokinetic study","volume":"20","author":"Dotan","year":"2014","journal-title":"Inflamm Bowel Dis"},{"key":"2026072304012636500_CIT0069","doi-asserted-by":"crossref","first-page":"1144","DOI":"10.1093\/ecco-jcc\/jjw079","article-title":"Relationship of body mass index to clinical outcomes after infliximab therapy in patients with Crohn\u2019s disease","volume":"10","author":"Brown","year":"2016","journal-title":"J Crohns Colitis"},{"key":"2026072304012636500_CIT0070","doi-asserted-by":"crossref","first-page":"622","DOI":"10.1097\/MEG.0000000000002371","article-title":"BMI is important in predicting the loss of response in inflammatory bowel disease patients on tumour necrosis factor-\u03b1 inhibitors","volume":"34","author":"Chuck","year":"2022","journal-title":"Eur J Gastroenterol Hepatol"},{"key":"2026072304012636500_CIT0071","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1177\/1060028019900660","article-title":"Associations between obesity and the effectiveness of anti\u2013tumor necrosis factor-\u03b1 agents in inflammatory bowel disease patients: a literature review and meta-analysis","volume":"54","author":"Dai","year":"2020","journal-title":"Ann Pharmacother"},{"key":"2026072304012636500_CIT0072","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1002\/jgh3.12277","article-title":"High body mass index is not associated with increased treatment failure in infliximab treated pediatric patients with inflammatory bowel disease","volume":"4","author":"Rodin","year":"2020","journal-title":"JGH Open"},{"key":"2026072304012636500_CIT0073","doi-asserted-by":"crossref","first-page":"1472","DOI":"10.1111\/apt.14665","article-title":"High body mass index is associated with increased risk of treatment failure and surgery in biologic-treated patients with ulcerative colitis","volume":"47","author":"Kurnool","year":"2018","journal-title":"Aliment Pharmacol Ther"},{"key":"2026072304012636500_CIT0074","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1038\/s41395-018-0104-x","article-title":"Obesity and response to infliximab in patients with inflammatory bowel diseases: pooled analysis of individual participant data from clinical trials","volume":"113","author":"Singh","year":"2018","journal-title":"Am J Gastroenterol"},{"key":"2026072304012636500_CIT0075","doi-asserted-by":"crossref","first-page":"2409","DOI":"10.1172\/JCI117936","article-title":"Increased adipose tissue expression of tumor necrosis factor-\u03b1 in human obesity and insulin resistance","volume":"95","author":"Hotamisligil","year":"1995","journal-title":"J Clin Invest"},{"key":"2026072304012636500_CIT0076","doi-asserted-by":"crossref","first-page":"848","DOI":"10.1097\/00054725-200411000-00019","article-title":"Inflammatory bowel disease and smoking: a review of epidemiology, pathophysiology, and therapeutic implications","volume":"10","author":"Birrenbach","year":"2004","journal-title":"Inflamm Bowel Dis"},{"key":"2026072304012636500_CIT0077","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1093\/ecco-jcc\/jju018","article-title":"Smoking and early infliximab response in Crohn\u2019s disease: a meta-analysis","volume":"9","author":"Inamdar","year":"2015","journal-title":"J Crohns Colitis"},{"key":"2026072304012636500_CIT0078","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1093\/ecco-jcc\/jjaa139","article-title":"Smoking may reduce the effectiveness of anti-TNF therapies to induce clinical response and remission in Crohn\u2019s disease: a systematic review and meta-analysis","volume":"15","author":"Lee","year":"2021","journal-title":"J Crohns Colitis"},{"key":"2026072304012636500_CIT0079","doi-asserted-by":"crossref","first-page":"158","DOI":"10.5217\/ir.2020.00008","article-title":"The impact of tobacco smoking on treatment choice and efficacy in inflammatory bowel disease","volume":"19","author":"Nicolaides","year":"2021","journal-title":"Intest Res"},{"key":"2026072304012636500_CIT0080","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1016\/S2468-1253(24)00044-X","article-title":"Mechanisms and management of loss of response to anti-TNF therapy for patients with Crohn\u2019s disease: 3-year data from the prospective, multicentre PANTS cohort study","volume":"9","author":"Chanchlani","year":"2024","journal-title":"Lancet Gastroenterol Hepatol"}],"container-title":["Journal of Crohn's and Colitis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ecco-jcc\/advance-article-pdf\/doi\/10.1093\/ecco-jcc\/jjae192\/61239994\/jjae192.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ecco-jcc\/article-pdf\/19\/5\/jjae192\/61239994\/jjae192.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ecco-jcc\/article-pdf\/19\/5\/jjae192\/61239994\/jjae192.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,23]],"date-time":"2026-07-23T08:01:40Z","timestamp":1784793700000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ecco-jcc\/article\/doi\/10.1093\/ecco-jcc\/jjae192\/7928947"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12,19]]},"references-count":80,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2025,5,8]]}},"URL":"https:\/\/doi.org\/10.1093\/ecco-jcc\/jjae192","relation":{},"ISSN":["1873-9946","1876-4479"],"issn-type":[{"value":"1873-9946","type":"print"},{"value":"1876-4479","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,5]]},"published":{"date-parts":[[2024,12,19]]},"article-number":"jjae192"}}